GR852877B - - Google Patents

Info

Publication number
GR852877B
GR852877B GR852877A GR850102877A GR852877B GR 852877 B GR852877 B GR 852877B GR 852877 A GR852877 A GR 852877A GR 850102877 A GR850102877 A GR 850102877A GR 852877 B GR852877 B GR 852877B
Authority
GR
Greece
Application number
GR852877A
Other languages
Greek (el)
Inventor
Andrew John Garman
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10570497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR852877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of GR852877B publication Critical patent/GR852877B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GR852877A 1984-11-30 1985-11-29 GR852877B (en, 2012)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848430252A GB8430252D0 (en) 1984-11-30 1984-11-30 Compounds

Publications (1)

Publication Number Publication Date
GR852877B true GR852877B (en, 2012) 1986-03-31

Family

ID=10570497

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852877A GR852877B (en, 2012) 1984-11-30 1985-11-29

Country Status (9)

Country Link
US (1) US4935465A (en, 2012)
EP (1) EP0183503B1 (en, 2012)
JP (2) JPH0717517B2 (en, 2012)
AU (1) AU5044585A (en, 2012)
DE (1) DE3586313T2 (en, 2012)
DK (1) DK552285A (en, 2012)
GB (1) GB8430252D0 (en, 2012)
GR (1) GR852877B (en, 2012)
PT (1) PT81581B (en, 2012)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842868A (en) * 1986-09-26 1989-06-27 Helwing Robert F Covalently bonded active agents with carbonium ion base groups
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
NZ225880A (en) * 1987-08-21 1991-07-26 Wellcome Found A complex of polyethylene glycol and tissue plasminogen activator
JPH079429B2 (ja) * 1988-10-12 1995-02-01 財団法人化学及血清療法研究所 人工担体およびその製造方法
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
EP0395918A3 (en) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5767072A (en) * 1989-09-14 1998-06-16 Board Of Regents, The University Of Texas System Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DE69334156T2 (de) 1992-11-16 2008-04-10 Centocor, Inc. Verfahren zur Reduzierung der Immunogenizität der variablen Regionen von Antikörpern
DK0675727T3 (da) * 1992-12-10 2002-08-05 Enzon Inc Glycolipidenzympolymerkonjugater
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
PT730470E (pt) * 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
WO1996004340A1 (en) * 1994-08-04 1996-02-15 Gordon George Wallace Conducting electroactive biomaterials
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5856451A (en) * 1994-12-07 1999-01-05 Novo Nordisk A/S Method for reducing respiratory allergenicity
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
JP4193917B2 (ja) 1995-12-18 2008-12-10 アンジオデバイス インターナショナル ゲーエムベーハー 架橋ポリマー組成物およびその使用方法
EP0874893A2 (en) * 1995-12-29 1998-11-04 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
WO1997030148A1 (en) * 1996-02-15 1997-08-21 Novo Nordisk A/S Conjugation of polypeptides
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
AU4907897A (en) * 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
JPH10276776A (ja) * 1997-04-07 1998-10-20 Toyobo Co Ltd 可逆的に不活化された耐熱性ｄｎａポリメラーゼ
JP2002514411A (ja) 1998-05-08 2002-05-21 ユニバーシティ オブ サザン カリフォルニア サイズ拡大型繊維素溶解酵素、及び繊維素溶解酵素のサイズ変更方法
DE69927971T2 (de) * 1998-06-08 2006-07-27 F. Hoffmann-La Roche Ag Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR100642955B1 (ko) 1999-04-23 2006-11-10 알자 코포레이션 방출성 결합 및 그를 함유하는 조성물
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
AU5805500A (en) * 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
US6423666B1 (en) 1999-10-05 2002-07-23 Bio-Rad Laboratories, Inc. Large-pore chromatographic beads prepared by suspension polymerization
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
DK1250154T3 (da) 2000-01-10 2009-08-17 Maxygen Holdings Ltd G-CSF-konjugater
NZ521257A (en) 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
ATE432288T1 (de) 2001-02-27 2009-06-15 Maxygen Aps Neue interferon-beta-ähnliche moleküle
GB0123232D0 (en) * 2001-09-26 2001-11-21 Smith & Nephew Polymers
JP2005508162A (ja) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
ES2363205T3 (es) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
GB0305989D0 (en) * 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
ATE481420T1 (de) 2003-10-10 2010-10-15 Novo Nordisk As Il-21-derivate
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
NZ586034A (en) 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
MXPA06012144A (es) * 2004-04-21 2007-01-31 Alza Corp Conjugado polimerico liberable bajo condiciones tioliticas suaves.
WO2006083260A2 (en) 2004-04-28 2006-08-10 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
WO2006034128A2 (en) 2004-09-17 2006-03-30 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
CN101484576A (zh) 2006-05-24 2009-07-15 诺沃-诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN101568350B (zh) 2006-10-27 2013-11-06 沈维强 脂质化干扰素及其应用
KR101808787B1 (ko) 2007-03-30 2017-12-13 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2009036349A1 (en) * 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
MX2010004400A (es) 2007-10-23 2010-05-20 Nektar Therapeutics Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
CA2705160A1 (en) * 2007-11-09 2009-05-14 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
KR101732054B1 (ko) 2008-09-26 2017-05-02 암브룩스, 인코포레이티드 비천연 아미노산 복제 의존성 미생물 및 백신
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
JP2012504969A (ja) 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US20110318322A1 (en) * 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
EP2516454A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND ITS USES
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JP2014513128A (ja) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
BR112014000055A2 (pt) 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
GB201117428D0 (en) * 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
CN114853868A (zh) 2014-10-24 2022-08-05 百时美施贵宝公司 修饰的fgf-21多肽及其用途
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11472771B2 (en) 2018-06-21 2022-10-18 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
JP7441826B2 (ja) 2018-09-11 2024-03-01 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド抱合物およびその使用
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
BR112021020226A2 (pt) 2019-04-10 2021-12-07 Cellestia Biotech Ag Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres
CN115243726B (zh) 2020-03-11 2025-07-15 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
TW202144419A (zh) 2020-03-24 2021-12-01 美商建南德克公司 Ｔｉｅ２結合劑及其使用方法
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
CN112451681B (zh) * 2020-12-09 2023-08-25 苏州大学 酸敏感型聚合物-药物偶联物及其制备和应用
EP4313163A1 (en) 2021-04-03 2024-02-07 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
US20250000870A1 (en) 2021-11-08 2025-01-02 Cellestia Biotech Ag Pharmaceutical Combinations for Treating Cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH453709A (de) * 1964-12-05 1968-03-31 Cassella Farbwerke Mainkur Ag Verfahren zur Anlagerung von Maleinsäureanhydrid an Polyalkylenäther
GB1390716A (en) * 1972-06-27 1975-04-16 Mitsubishi Electric Corp Ester of trimellitic anhydride and process for producing the same
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3160926D1 (en) * 1980-04-15 1983-10-27 Beecham Group Plc Allergens modified with polysarcosines
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4859736A (en) * 1987-03-30 1989-08-22 Ciba-Geigy Corporation Synthetic polystyrene resin and its use in solid phase peptide synthesis

Also Published As

Publication number Publication date
EP0183503A2 (en) 1986-06-04
JPH0717517B2 (ja) 1995-03-01
PT81581A (en) 1985-12-01
DK552285A (da) 1986-05-31
JPS61155333A (ja) 1986-07-15
PT81581B (en) 1987-07-22
JPH06279318A (ja) 1994-10-04
DE3586313D1 (de) 1992-08-13
EP0183503A3 (en) 1988-01-07
GB8430252D0 (en) 1985-01-09
AU5044585A (en) 1986-07-17
DE3586313T2 (de) 1993-01-21
JP2545339B2 (ja) 1996-10-16
DK552285D0 (da) 1985-11-28
US4935465A (en) 1990-06-19
EP0183503B1 (en) 1992-07-08

Similar Documents

Publication Publication Date Title
GR852877B (en, 2012)
GR852232B (en, 2012)
GR850850B (en, 2012)
GR851499B (en, 2012)
GR850161B (en, 2012)
GR850337B (en, 2012)
GR851415B (en, 2012)
GR852125B (en, 2012)
GR850972B (en, 2012)
IN162054B (en, 2012)
GR851730B (en, 2012)
GR79996B (en, 2012)
IN161560B (en, 2012)
BG44917A1 (en, 2012)
BG44737A1 (en, 2012)
BG44829A1 (en, 2012)
BG44806A1 (en, 2012)
BG44848A1 (en, 2012)
BG45166A1 (en, 2012)
BG44933A1 (en, 2012)
BG44935A1 (en, 2012)
BG45025A1 (en, 2012)
BG45054A1 (en, 2012)
BG45060A1 (en, 2012)
BG45079A1 (en, 2012)